Abstracts Archive

The AITL cell-of-origin, a T-follicular helper cell (TFH), has a set of mutations also found in some PTCL-NOS; this similarity has led to a reclassification (WHO 5th edition), grouping AITL, PTCL-NOS w/TFH phenotype, and follicular-T-cell lymphoma together as nodal TFH lymphoma (nTFHL). Duvelisib i...

Background: Cutaneous T-cell lymphoma (CTCL) are a heterogeneous group of lymphoproliferative disorders characterized by malignant atypical clonal T lymphocytes with skin involvement, most commonly including mycosis fungoides (MF) and Sezary Syndrome (SS).  MF and SS are difficult to treat...

Introduction: PTPN2 was identified as the essential gene for the growth and survival of ALK+ALCL based on the results of the whole genome loss of function screens in ALK+ALCL cells (SUDHL1, Karpas299, KIJK, SUPM2 and DEL). The first in class potent PTPN2/1 active site inhibitor ABBV CLS 484 (AC484) ...

Chemotherapy resistance in ENKTCL is poorly understood. We hypothesized that integrated omics would uncover molecular drivers of refractoriness to therapy in a topographically diverse series of cases with distinct treatment responses.We performed WGS(60x), WES(150-300x), and bulk RNA-seq on 52 ...

Large granular lymphocyte leukemia (LGLL) is a rare type of leukemia that is most prevalent in the elderly population. Standard-of-care treatments include immunosuppressive therapies such as methotrexate, cyclosporine, or cyclophosphamide, but response rates are only modest, and toxicity such as cyt...

The JAK/STAT pathway is frequently dysregulated in PTCL and CTCL, resulting in uncontrolled signaling, cell proliferation, and disease progression. Recently, the JAK/STAT pathway has emerged as a promising therapeutic target, with inhibitors such as ruxolitinib and golidocitinib demonstrating clinic...

PURPOSE: Functional precision medicine approaches, including ex vivo drug sensitivity, may improve individualized treatment selection. This is useful for T-cell lymphoma (TCL), which has limited treatment options and is more prevalent in Asian countries. In a previously published clinical feasibilit...

Introduction: T-cell lymphomas (TCL) is a rare and aggressive form of non-Hodgkin's lymphoma characterized by the malignant proliferation of T-cells. Despite recent advances in understanding the disease biology and development of novel therapies, PTCL remains a challenging clinical entity. ...